Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Ginkgo Bioworks Holdings Inc のCEOは誰ですか？
Dr. Jason Kelly は Ginkgo Bioworks Holdings Inc の Chief Executive Officer で、2021 から在籍しています。
DNA の株価パフォーマンスは？
DNA の現在の価格は $13.56 で、最終取引日から 0.05% decreased 変動しました。
Ginkgo Bioworks Holdings Inc の主な事業テーマや業界は？
Ginkgo Bioworks Holdings Inc は Life Sciences Tools & Services 業界、セクターは Health Care に属しています。
